Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

    Circulation Date published:

  • Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

    Diabetologia Date published:

  • Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease

    Annals of Internal Medicine Date published:

  • Blood pressure: at what level is treatment worthwhile?

    Australian Prescriber Date published:

  • The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

    Diabetologia Date published:

  • Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study

    BMC Nephrology Date published:

  • GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

    Journal of the American Society of Nephrology Date published:

  • Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial

    Journal of Renal Nutrition Date published:

  • Is it time to REWIND the cardiorenal clock in diabetes?

    The Lancet Date published:

  • Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

    New England Journal of Medicine Date published:

  • Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes

    Clinical Journal of the American Society of Nephrology Date published:

  • 1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program

    Diabetes Date published:

  • 1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program

    Diabetes Date published:

  • 388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial

    Diabetes Date published:

  • 432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease

    Diabetes Date published:

  • Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria

    Journal of Hypertension Date published: